Multiple Sclerosis Clinical Trial
Official title:
High-Intensity, Dynamic-stability Gait Training in People With Multiple Sclerosis
The goal of this clinical trial is to improve walking speed, balance, and walking in the community for people with multiple sclerosis. This trial involves intense exercise combined with walking on a shaky treadmill. Walking on a shaky treadmill helps to practice balance and intense exercise promotes the ability to walk faster and farther. In this study, participants will train with a combination of high or low intensity, and with a stable or shaky treadmill. Walking speed and endurance, balance while walking and the number of steps taken in the community will be measured before, half way through the training (15 sessions), after training (30 sessions) and six months after training.
Status | Recruiting |
Enrollment | 150 |
Est. completion date | June 30, 2027 |
Est. primary completion date | June 30, 2027 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 75 Years |
Eligibility | Inclusion Criteria: 1. Participants must have a clinical diagnosis of MS according to the revised McDonald Criteria. Participants with an EDSS score of 2.0-6.5 will be included but must have a stable disease course without worsening more than 1.0 EDSS point over the last 3 months and no MS exacerbation within the preceding 4 weeks, as determined by interview and review of medical records. 2. Participants will have stable MS disease treatments. All medications will be consistent for at least 1 month prior to enrollment. No corticosteroids for at least 1 month and no botulinum toxin injections above the knee for at least 3 months prior to enrollment. 3. Participants will be between the age of 18 and 65 and have a body mass of less than 135kg (maximum mass for treadmill equipment). 4. Participants will be able to follow three commands, as determined by the three step command test of the Mini Mental State Exam. 5. Participants must have had no myocardial infarction in the past month, must not have uncontrolled hypertension (blood pressure must be < 190/110 mmHg at rest), must not have a symptomatic fall in blood pressure when standing and must not have documented, uncontrolled diabetes. 6. Participants will be medically stable, with absence of concurrent severe medical illness including: existing infection, known significant cardiovascular or metabolic disease that limits exercise participation, significant osteoporosis (as indicated by known history of fractures), known history of vascular claudication or pitting edema, and known history of pulmonary complications that limits exercise capacity, including significant obstructive and/or restrictive lung diseases. 7. All participants must be able to perform walking training with passive range of motion within the limits of normal locomotor function, including: 0-30 +/- 10 degrees ankle plantarflexion, knee flexion from 0 to 90 +/- 10 degrees, hip flexion to 0-90 +/- 10 degrees. 8. Individuals who are undergoing concurrent physical therapy or supervised exercise by a trained professional will be excluded from the study to eliminate confounding effects of additional physical interventions. Other therapies, such as occupational or speech therapies, will be allowed as prescribed by their physician. Individuals will be allowed and encouraged to continue their normal exercise routines during the course of the intervention. 9. Participants must have no other concomitant neurological diseases, no history of epileptic seizures, peripheral nerve injury in lower legs or traumatic brain injury. 10. Participants must have adequate hearing (whisper test) and vision (minimum 20/80 corrected vision on a Snellen chart). 11. Participants must be able to walk for 10 meters at their preferred walking speed. For participants that require assistive devices to walk overground, minimal assistance will be provided to enable training until participants recover enough that they are not needed. The use of braces or orthoses is allowed in the proposed study to assure orthopedic safety. Participants will be excluded if they have factors that preclude stepping exercise, such as severe spasticity, excessive fatigue or exercise intolerance. 12. Women of childbearing potential will not be excluded, although women who are pregnant or who are considering becoming pregnant will be excluded due to the trunk and pelvis restraints required for safety during treadmill training. 13. Participants must be willing to commit to the treadmill training program schedule and participate in all of the assessments. They must be able to provide informed written consent and willing to be randomized to any of the 4 study arms. Exclusion Criteria: See inclusion criteria. |
Country | Name | City | State |
---|---|---|---|
United States | Rehabilitation Hospital of Indiana | Indianapolis | Indiana |
United States | Marquette University | Milwaukee | Wisconsin |
Lead Sponsor | Collaborator |
---|---|
Marquette University | Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), Indiana University, Medical College of Wisconsin |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Changes in Timed 25-foot walk test | Gait speed will be measured using the timed 25-foot walk test. The test consists of walking 25 feet along a clearly marked walkway as quickly as possible while maintaining safety, using devices as needed. The task is repeated as the patient walks back the same distance. The average of the two trials is used as a measure of gait speed. | Before training, 5-6 weeks after training begins, 1-2 weeks after all training sessions, 6 months after all training sessions | |
Primary | Changes in 6-minute walk test | The 6 minute walk test consists of a measurement of the distance walked in 6 minutes, using a walkway of at least 12 meters, with cones demarcating the turnaround points and instructions to walk as fast and as far as possible. | Before training, 5-6 weeks after training begins, 1-2 weeks after all training sessions, 6 months after all training sessions | |
Primary | Changes in Functional Gait Assessment (FGA) | The FGA measures dynamic balance during walking using a series of 10 tasks, with each item rated on a scale of 0-3 (maximum score = 30). Test components include walking on a level surface at normal pace with changes in gait speed, head turns, obstacle and narrow path negotiation, and on stairs. | Before training, 5-6 weeks after training begins, 1-2 weeks after all training sessions, 6 months after all training sessions | |
Primary | Changes in Daily stepping activity | Daily stepping activity will be obtained using the StepWatch (Modus, Washington DC), which is an ankle-worn accelerometer that has demonstrated the best accuracy of all commercial accelerometers. Data are collected in 1 min increments with daily stepping activity as the primary variable. Data will be collected for 7 days at each evaluation period. | Before training, 1-2 weeks after all training sessions, 6 months after all training sessions | |
Secondary | Changes in Peak treadmill speed and cardiorespiratory fitness | VO2peak and VO2gain ml/mg/min will be assessed during graded treadmill testing. Participants will walk at 0.1 m/s for 1 min, with speed increased by 0.1 m/s every minute. Metabolic data will be collected on a breath-by-breath basis until treadmill testing is terminated, as determined by loss of balance, patient intolerance, or abnormal ECG recording consistent with absolute contraindications to continue testing. The averaged VO2 during the final minute of treadmill testing at peak speed will be determined (VO2peak). Baseline VO2peak and VO2 at the matched speed Post-training (VO2match) will be used to identify changes in metabolic efficiency. The difference between gains in VO2peak and VO2match will be identified as VO2 gain. | Before training, 5-6 weeks after training begins, 1-2 weeks after all training sessions, 6 months after all training sessions | |
Secondary | Changes in Berg Balance Scale | The Berg Balance Scale (BBS) will be used to assess standing balance and determine whether walking balance training carries over to standing balance. The BBS consists of 14 static and dynamic balance tasks of varying difficulty, rated on a scale of 0-4 by an assessor (max score = 56). | Before training, 5-6 weeks after training begins, 1-2 weeks after all training sessions, 6 months after all training sessions | |
Secondary | Changes in Falls incidence | A survey of Falls incidence will be administered at Baseline to estimate the number of falls in the past 6 months. At this time, participants will be issued a journal to document falls for the duration of the training study and for 6 months after training has been completed. Study staff will contact participants every month to assure compliance. | Before training, 5-6 weeks after training begins, 1-2 weeks after all training sessions, 6 months after all training sessions | |
Secondary | Changes in Kinematic Response to unexpected perturbations | Responses to 5 magnitudes of perturbations of the treadmill in 4 directions will be measured using a whole body motion capture. Center of Mass movement and foot placement (Base of Support) will be calculated and medial/lateral margin of stability and anterior/posterior dynamic gait stability will be used to assess the response. Step sizes and trunk angles will be quantified. | Before training, 5-6 weeks after training begins, 1-2 weeks after all training sessions, 6 months after all training sessions | |
Secondary | Changes in Activities-specific Balance Confidence (ABC) score | The ABC is a self-report on 16 items, with each item beginning with the phrase 'How confident are you that you will not lose your balance or become unsteady when you ….'. Each item is rated from a score of 0 (no confidence) to 100 (complete confidence) and the items are averaged to obtain a score (max =100) | Before training, 5-6 weeks after training begins, 1-2 weeks after all training sessions, 6 months after all training sessions | |
Secondary | Changes in Medical Outcomes Short-Form 36 (SF-36) Version 2 | The Medical Outcomes Short-Form 36 (SF-36) is a 36-item questionnaire that is divided into 8 subscales and 2 composite domains (SF-36-Physical and SF-36-Mental) and consists of Likert-type items that assess subjective physical and mental capacity and well-being over the past 4 weeks. Scales are standardized by the SF-36v2 scoring software to obtain a score ranging from 0 to 100 with higher scores indicating better health status. | Before training, 5-6 weeks after training begins, 1-2 weeks after all training sessions, 6 months after all training sessions | |
Secondary | Changes in Peak Stepping Rate | Stepping activity from the StepWatch will be collected and analyzed to assess the pattern of community stepping. Secondary measures of stepping activity will include peak stepping rate (steps/min). | Before training, 1-2 weeks after all training sessions, 6 months after all training sessions | |
Secondary | Changes in Total Bouts of Stepping | Stepping activity from the StepWatch will be collected and analyzed to assess the pattern of community stepping. Secondary measures of stepping activity will include total bouts of stepping. | Before training, 1-2 weeks after all training sessions, 6 months after all training sessions | |
Secondary | Changes in Average Duration of Stepping Bouts | Stepping activity from the StepWatch will be collected and analyzed to assess the pattern of community stepping. Secondary measures of stepping activity will include average duration of stepping bouts (i.e., bout = period of stepping without rest). | Before training, 1-2 weeks after all training sessions, 6 months after all training sessions |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05528666 -
Risk Perception in Multiple Sclerosis
|
||
Completed |
NCT03608527 -
Adaptive Plasticity Following Rehabilitation in Multiple Sclerosis
|
N/A | |
Recruiting |
NCT05532943 -
Evaluate the Safety and Efficacy of Allogeneic Umbilical Cord Mesenchymal Stem Cells in Patients With Multiple Sclerosis
|
Phase 1/Phase 2 | |
Completed |
NCT02486640 -
Evaluation of Potential Predictors of Adherence by Investigating a Representative Cohort of Multiple Sclerosis (MS) Patients in Germany Treated With Betaferon
|
||
Completed |
NCT01324232 -
Safety and Efficacy of AVP-923 in the Treatment of Central Neuropathic Pain in Multiple Sclerosis
|
Phase 2 | |
Completed |
NCT04546698 -
5-HT7 Receptor Implication in Inflammatory Mechanisms in Multiple Sclerosis
|
||
Active, not recruiting |
NCT04380220 -
Coagulation/Complement Activation and Cerebral Hypoperfusion in Relapsing-remitting Multiple Sclerosis
|
||
Completed |
NCT02835677 -
Integrating Caregiver Support Into MS Care
|
N/A | |
Completed |
NCT03686826 -
Feasibility and Reliability of Multimodal Evoked Potentials
|
||
Recruiting |
NCT05964829 -
Impact of the Cionic Neural Sleeve on Mobility in Multiple Sclerosis
|
N/A | |
Withdrawn |
NCT06021561 -
Orofacial Pain in Multiple Sclerosis
|
||
Completed |
NCT03653585 -
Cortical Lesions in Patients With Multiple Sclerosis
|
||
Recruiting |
NCT04798651 -
Pathogenicity of B and CD4 T Cell Subsets in Multiple Sclerosis
|
N/A | |
Active, not recruiting |
NCT05054140 -
Study to Evaluate Efficacy, Safety, and Tolerability of IMU-838 in Patients With Progressive Multiple Sclerosis
|
Phase 2 | |
Completed |
NCT05447143 -
Effect of Home Exercise Program on Various Parameters in Patients With Multiple Sclerosis
|
N/A | |
Recruiting |
NCT06195644 -
Effect of Galvanic Vestibular Stimulation on Cortical Excitability and Hand Dexterity in Multiple Sclerosis Patients
|
Phase 1 | |
Completed |
NCT04147052 -
iSLEEPms: An Internet-Delivered Intervention for Sleep Disturbance in Multiple Sclerosis
|
N/A | |
Completed |
NCT03591809 -
Combined Exercise Training in Patients With Multiple Sclerosis
|
N/A | |
Completed |
NCT03594357 -
Cognitive Functions in Patients With Multiple Sclerosis
|
||
Completed |
NCT03269175 -
BENEFIT 15 Long-term Follow-up Study of the BENEFIT and BENEFIT Follow-up Studies
|
Phase 4 |